Psychedelics in Psychiatry

Join Genomind and guest speaker, Dr. Cody Wenthur, as we discuss psychedelic use in psychiatry.

Cody Wenthur, PharmD, PhD is Assistant Professor of Pharmacy and Director, Psychoactive Pharmaceutical Investigation MS Program, School of Pharmacy, University of Wisconsin-Madison. He completed training at Purdue, Vanderbilt, and Scripps, which included clinical work in inpatient psychiatric units, mechanistically novel academic drug discovery efforts, and the search for biomarkers of response to vaccines directed against abusable psychoactive substances.

The Wenthur laboratory is currently exploring how the immune system can alter the function of brain reward systems, as a means to develop new therapeutics for addiction and associated psychiatric illnesses. Within this overall effort, there are multiple interconnected projects crafted to support rapid translation of these findings and improve human health. These projects include the development of novel bioconjugate vaccines and monoclonal antibodies that can block the effects of abused synthetic and naturally-derived drugs, the use of antibody-mediated techniques to understand how multiple compounds and neurochemical systems interact to support maladaptive learning during chronic stress in mammalian systems, and the identification of immune-mediated biomarkers of ongoing drug abuse in humans, especially prescription opioids, and to understand how these alterations in immune function affect the efficacy of these abused drugs.

In this 1-hour session, Dr. Wenthur presents on psychedelics in psychiatry, then concludes with a Q&A session.